trending Market Intelligence /marketintelligence/en/news-insights/trending/tl7j7Sm6EuxvJNsSQD_-fA2 content esgSubNav
In This List

INSYS Therapeutics' cannabis treatment receives US FDA's fast track designation

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


INSYS Therapeutics' cannabis treatment receives US FDA's fast track designation

INSYS Therapeutics Inc.'s cannabis treatment to treat the Prader-Willi syndrome received the U.S. Food and Drug Administration's fast track designation.

Prader-Willi syndrome is a rare genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes.

The company plans to start clinical development of its oral investigational treatment in the late first quarter of 2018.